Stanford, CA, United States

Stanford University

www.stanford.edu
Stanford, CA, United States

Leland Stanford Junior University, or more commonly Stanford University, is a private research university in Stanford, California, and one of the world's most prestigious institutions, with the highest undergraduate selectivity and the top position in numerous surveys and measures in the United States.Stanford was founded in 1885 by Leland Stanford, former governor of and U.S. senator from California and leading railroad tycoon, and his wife, Jane Lathrop Stanford, in memory of their only child, Leland Stanford, Jr., who had died of typhoid fever at age 15 the previous year. Stanford was opened on October 1, 1891 as a coeducational and non-denominational institution. Tuition was free until 1920. The university struggled financially after Leland Stanford's 1893 death and after much of the campus was damaged by the 1906 San Francisco earthquake. Following World War II, Provost Frederick Terman supported faculty and graduates' entrepreneurialism to build self-sufficient local industry in what would later be known as Silicon Valley. By 1970, Stanford was home to a linear accelerator, and was one of the original four ARPANET nodes .Stanford is located in northern Silicon Valley near Palo Alto, California. The University's academic departments are organized into seven schools, with several other holdings, such as laboratories and nature reserves, located outside the main campus. Its 8,180-acre campus is one of the largest in the United States. The University is also one of the top fundraising institutions in the country, becoming the first school to raise more than a billion dollars in a year.Stanford's undergraduate program is the most selective in the country with an acceptance rate of 5.07% for the 2018 Class. Students compete in 36 varsity sports, and the University is one of two private institutions in the Division I FBS Pacific-12 Conference. It has gained 105 NCAA team championships, the second-most for a university, 465 individual championships, the most in Division I, and has won the NACDA Directors' Cup, recognizing the university with the best overall athletic team achievement, every year since 1994-1995.Stanford faculty and alumni have founded many companies including Google, Hewlett-Packard, Nike, Sun Microsystems, and Yahoo!, and companies founded by Stanford alumni generate more than $2.7 trillion in annual revenue, equivalent to the 10th-largest economy in the world. Fifty-nine Nobel laureates have been affiliated with the University, and it is the alma mater of 30 living billionaires and 17 astronauts. Stanford has produced a total of 18 Turing Award laureates, the highest in the world for any one institution. It is also one of the leading producers of members of the United States Congress. Wikipedia.


Time filter

Source Type

Patent
Stanford University | Date: 2017-03-29

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided


Patent
Vib Vzw, Vrije Universiteit Brussel and Stanford University | Date: 2017-01-18

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.


A 1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a 1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the 1-ADR agonist compound.


Stimulation of target cells using light, e.g., in vivo, is implemented using a variety of methods and devices. In one such device, target cells are stimulated using an implantable device. The device includes a light source for producing light from electrical power. An optical transmission element is made from a material that is substantially transparent to the light from the light source. This transmission element substantially encases the light source at a proximal end. The transmission element delivers light from the light source to a distal end. The shape and size of the transmission element facilitates implanting of the element within a patient. A fixation portion physically couples to the optical transmission element and secures the device to the patient. A heat dissipation portion removes heat from the near optical transmission element and the light source and dissipates the removed heat through the fixation portion.


The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.


Patent
Stanford University | Date: 2017-01-13

Engineered sortase variants are shown to have promiscuous activity that allow proteins to be tagged using a diverse array of small, commercially available amines, including bioorthogonal functional groups. This technique can also be carried out in living microbial cells, enabling simple, inexpensive production of chemically functionalized proteins with no additional purification steps. The methods find use in the site specific conjugation of drugs, imaging probes and other chemical moieties to proteins and peptides.


Patent
Stanford University | Date: 2017-03-28

The present disclosure provides a method of inducing or modulating reward- or aversive-related behaviors in animals using light-responsive opsins. The present disclosure provides methods of identifying or screening compounds that may be used to treating mental disorders, or are relevant to disrupt or improve reward- or aversive related behaviors.


Patent
Stanford University | Date: 2017-07-19

Methods are provided for stimulating ovarian follicles in a mammal through activation of the mTor signaling pathway.


Patent
Stanford University | Date: 2017-05-24

A cathode for water splitting production includes: (1) a porous substrate; and (2) an electrocatalyst affixed to the porous substrate. The electrocatalyst includes heterostructures of a first material and a second material that partially covers the first material.


Steinman L.,Stanford University
Annual Review of Immunology | Year: 2014

Eighty percent of individuals with multiple sclerosis (MS) initially develop a clinical pattern with periodic relapses followed by remissions, called relapsing-remitting MS (RRMS). This period of fluctuating disease may last for a decade or more. Clinical relapses reflect acute inflammation in the central nervous system (CNS), composed of the brain and spinal cord. Often, different anatomic areas in the CNS are involved each time a relapse occurs, resulting in varied clinical manifestations in each instance. Relapses are nearly always followed by some degree of remission, though recovery to baseline status before the flare is often incomplete. There are nine approved drugs for treatment of RRMS. The most potent drug for inhibiting relapses, the humanized anti-α4 integrin antibody known as Natalizumab, blocks homing of mononuclear cells to the CNS. The mechanisms of action of the approved drugs for RRMS provide a strong foundation for understanding the pathobiology of the relapse. Despite substantial progress in controlling relapses with the current armamentarium of medications, there is much to learn and ever more effective and safe therapies to develop. © 2014 by Annual Reviews. All rights reserved.

Loading Stanford University collaborators
Loading Stanford University collaborators